阴茎海绵体内注射治疗相关阴茎异常勃起的临床特征与管理结局
ICI相关病例中75.4%为急性缺血性、24.5%为复发性缺血性;结论提示ICI相关异常勃起对勃起功能障碍管理决策影响显著,娱乐性使用与不良结局相关。
要点
- ICI相关异常勃起以急性缺血性为主,娱乐性使用者就诊延迟最明显。
- 勃起持续时间中位数:诊室内3小时、处方7小时、娱乐性30小时。
- 57%患者因此停用处方形ICI,65%既往未受累的娱乐性使用者出现新发ED。
核心结论
- ICI相关阴茎异常勃起是重要临床问题,勃起持续时间因诊室内、处方与娱乐性使用场景不同而差异显著。
- 异常勃起后ICI停药率高,对新发ED的关联提示需针对娱乐性使用开展临床 outreach 与风险干预。
研究设计与样本
- 共186例阴茎异常勃起,其中102例(54.8%)为ICI相关,按急性缺血性、复发性缺血性或非缺血性分类并按注射场景分层。
- 采用描述性统计分析人口学、临床表现、管理策略与勃起功能结局。
主要发现
- ICI相关病例中75.4%为急性缺血性,24.5%为复发性缺血性,平均复发2.5±0.7次。
- 诊室内注射与处方注射各占39.2%,娱乐性使用占21.6%。
- 57%患者停用处方形ICI,65%既往未受累的娱乐性使用者出现新发ED。
关键数值与推荐
- ICI相关阴茎异常勃起102例(占全部186例的54.8%)。
- 急性缺血性75.4%、复发性缺血性24.5%,平均复发2.5±0.7次。
- 诊室内与处方注射各39.2%,娱乐性21.6%。
- 停药率57%,娱乐性使用者新发ED率65%。
临床怎么用
- 接诊阴茎异常勃起时应询问ICI使用场景,娱乐性使用者常就诊延迟且合并HIV或药物使用。
- 对处方ICI患者异常勃起后需评估是否停药并重新规划ED治疗。
- 对娱乐性ICI使用者应加强风险告知与新发ED的随访。
局限性
- 单中心回顾性设计,结果外推需谨慎。
- 仅用描述性统计,未报告多因素校正结果。
- 摘要未报告非ICI相关病例的对照比较细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical characteristics, risk factors, and outcomes of priapism following intracavernosal injection (ICI) therapy, with specific focus on comparing in-office, prescribed, and recreational ICI patterns. METHODS: A retrospective review identified patients presenting with priapism (ICD-10: N48.3) at a single institution from November 2015 through September 2024. Cases were classified as acute ischemic, recurrent ischemic, or non-ischemic, and stratified by ICI administration setting: in-office, prescribed, or recreational. Demographics, clinical presentation, management strategies, and erectile function outcomes were analyzed using descriptive statistics. RESULTS: Of 186 priapism cases, 102 (54.8%) were ICI-related. Among these, 75.4% presented as acute ischemic and 24.5% as recurrent ischemic (mean 2.5 ± 0.7 recurrences). In-office and prescribed injections each accounted for 39.2% of cases, while recreational use comprised 21.6%. Median priapism duration varied significantly by setting: 3 hours (IQR: 2-4) for in-office, 7 hours (IQR: 6-12) for prescribed, and 30 hours (IQR: 12-63) for recreational use (P <.001). Recreational users demonstrated significantly higher rates of human immunodeficiency virus (HIV) and illicit drug use (P <.001). Post-priapism outcomes revealed that 57% of patients discontinued prescribed ICI therapy, while 65% of previously unaffected recreational users developed de novo erectile dysfunction. CONCLUSION: ICI-induced priapism represents a significant clinical challenge, with the duration of priapism varying markedly between in-office, prescribed, and recreational use. The high rate of ICI discontinuation following priapism suggests a substantial impact on ED management decisions. The association between recreational use and adverse outcomes, including de novo ED, identifies an important area for clinical outreach and risk mitigation strategies.
引用
- Borrell JA, Bettencourt A, Furtado TP, et al. Exploring the Clinical Landscape of Priapism Related to Intracavernosal Injection Therapy: Patient Characteristics, Management Patterns, and Erectile Dysfunction Outcomes. Urology. 2025. PMID: 40287023. doi:10.1016/j.urology.2025.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。